Amylin Pharmaceuticals to Present at Goldman Sachs Healthcare Conference
June 08 2007 - 5:05PM
PR Newswire (US)
SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (NASDAQ:AMLN) will be presenting at the Goldman Sachs
Healthcare Conference on Thursday, June 14, 2007 at 9:20 a.m. PT in
Laguna Nigel, CA. Daniel M. Bradbury, President and Chief Executive
Officer of Amylin Pharmaceuticals, will be providing a corporate
overview. The live presentation will be webcast, and a recording
will be made available following the event. The webcast and
recording will be accessible through Amylin's corporate website,
located at http://www.amylin.com/. To access the live webcast,
please log on to Amylin's site approximately fifteen minutes prior
to the presentation to register and download any necessary audio
software. About Amylin Pharmaceuticals Amylin Pharmaceuticals is a
biopharmaceutical company committed to improving lives through the
discovery, development and commercialization of innovative
medicines. Amylin has developed and gained approval for two first-
in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research
and development activities leverage the company's expertise in
metabolism to develop potential therapies to treat diabetes and
obesity. Amylin is located in San Diego, California with over 1,600
employees nationwide. For more information about Amylin visit
http://www.amylin.com/. DATASOURCE: Amylin Pharmaceuticals, Inc.
CONTACT: Alice Bahner Izzo, Executive Director, Corporate Affairs
of Amylin Pharmaceuticals, Inc., +1-858-552-2200, ext. 7272 Web
site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024